Millendo Therapeutics Appoints Habib Dable to Its Board of Directors
ANN ARBOR, Mich.--(BUSINESS WIRE)--Sep 25, 2018--Millendo Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointment of Habib Dable, President and Chief Executive Officer of Acceleron Pharma Inc., to the Company’s Board of Directors.
“Habib brings to our board an exceptional mix of executive and operational leadership experience, in addition to his strong commercial expertise, having launched multiple blockbuster medicines over the last two decades,” said Julia C. Owens, Ph.D., President and Chief Executive Officer of Millendo. “His experience will be especially valuable as we move into the next stage of Millendo’s growth, advancing livoletide into a pivotal Phase 2b/3 clinical trial for Prader-Willi syndrome.”
“It is a privilege to join Millendo’s board as the team works to address serious, orphan endocrine diseases with potentially transformative therapies, including its lead pipeline asset, livoletide for patients with Prader-Willi syndrome,” Mr. Dable said. “I look forward to working with the exceptional team at Millendo to optimize the value of livoletide and nevanimibe for patients and shareholders.”
Mr. Dable has served as the President and Chief Executive Officer of Acceleron Pharma since 2016. Prior to joining Acceleron, he spent more than 20 years at Bayer AG in a number of commercial and operational leadership roles, ending his tenure there as President of Pharmaceuticals in the U.S. In this role, he was responsible for several new product launches while managing Bayer AG’s multi-billion-dollar portfolio spanning therapeutic areas including hematology, neurology, oncology, women’s health, and cardiovascular disease. Prior to his role as President of U.S. Pharmaceuticals at Bayer AG, Mr. Dable was global head of specialty medicine for Bayer HealthCare Pharmaceuticals, where he was responsible for the global launch of multiple blockbuster brands, including EYLEA®, Stivarga® and Xofigo®. Mr. Dable recently served on the board of directors of the Biotechnology Innovation Organization (BIO). He received a B.B.A. in marketing and finance and his MBA from the University of New Brunswick.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is focused on developing novel treatments for orphan endocrine diseases. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005341/en/
CONTACT: Media Contact:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
Stephanie Ascher, 212-362-1200
Stern Investor Relations
KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Millendo Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 09/25/2018 08:00 AM/DISC: 09/25/2018 08:01 AM